Pfizer Form 3 / MICHAEL GOETTLER ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

GOETTLER MICHAEL

(Last)

(First)

(Middle)

PFIZER INC.-CORP. SECRETARY

235 EAST 42ND ST.

(Street)

NEW YORK

10017

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/01/2018

3. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Group President

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	31,122	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Phantom Stock Units SSP	⁽¹⁾	⁽¹⁾	Common Stock	1,899	⁽²⁾	D
Stock Appreciation Rights	02/23/2019⁽³⁾	02/23/2019⁽³⁾	Common Stock	19,290	21.03	D
Stock Appreciation Rights	02/28/2020⁽³⁾	02/28/2020⁽³⁾	Common Stock	22,852	27.37	D
Stock Appreciation Rights	02/25/2021⁽⁴⁾	02/25/2021⁽⁴⁾	Common Stock	21,552	30.59	D
Stock Appreciation Rights	02/25/2023⁽³⁾	02/25/2023⁽³⁾	Common Stock	19,260	30.59	D
Stock Appreciation Rights	02/27/2019⁽⁴⁾	02/27/2019⁽⁴⁾	Common Stock	30,017	32.23	D
Stock Appreciation Rights	02/27/2021⁽³⁾	02/27/2021⁽³⁾	Common Stock	23,907	32.23	D
Stock Appreciation Rights	02/23/2022⁽⁴⁾	02/23/2022⁽⁴⁾	Common Stock	20,292	34.06	D
Stock Appreciation Rights	02/23/2024⁽³⁾	02/23/2024⁽³⁾	Common Stock	16,846	34.06	D
Stock Appreciation Rights	02/26/2020⁽⁴⁾	02/26/2020⁽⁴⁾	Common Stock	20,129	34.59	D
Stock Appreciation Rights	02/26/2022⁽³⁾	02/26/2022⁽³⁾	Common Stock	16,779	34.59	D
Stock Appreciation Rights	02/22/2023⁽⁴⁾	02/22/2023⁽⁴⁾	Common Stock	18,061	35.74	D
Stock Appreciation Rights	02/22/2025⁽³⁾	02/22/2025⁽³⁾	Common Stock	15,099	35.74	D

Explanation of Responses:

1. These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

2. Each unit represents one phantom share of common stock.

3. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

4. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

Remarks:

poamg18.htm

	Susan E. Grant, by power of atty., for Michael Goettler	07/11/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Pfizer (PFE) Form 3PFIZER / MICHAEL GOETTLER ownership change